P1.09-09 Evaluation of a Novel ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in NSCLC Patients

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.08.785
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Non-Small Cell Lung Carcinoma Patients: The ROSING Study

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2019English

P2.09-13 Correlation of ROS1 (SP384) Immunohistochemistry With ROS1 Rearrangement Determined by Fluorescence in Situ Hybridization

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

MA26.07 ROS1 (SP384) Immunohistochemistry Inter-Reader Precision Between 12 Pathologists

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P1.09-12 Simultaneous Platform of Genotyping EGFR, ALK, and ROS1 in Patients With NSCLC Highlights Correlation of ROS1 and PD-L1 Expression

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

ROS1 Rearrangements Are Only Found in Lung Adenocarcinomas With Diffuse Strong IHC Expression of ROS1

Pathology
Forensic MedicinePathology
2020English

Ceritinib Beim ROS1-positiven NSCLC

Im Focus Onkologie
2017English

OA02.02 Safety and Preliminary Clinical Activity of Ropotrectinib (TPX-0005), a ROS1/TRK/ALK Inhibitor, in Advanced ROS1 Fusion-Positive NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

ROS1 Immunohistochemistry Among Major Genotypes of Non–Small-Cell Lung Cancer

Clinical Lung Cancer
Cancer ResearchOncologyRespiratory MedicinePulmonary
2015English

ROS1-ADGRG6: A Case Report of a Novel ROS1 Oncogenic Fusion Variant in Lung Adenocarcinoma and the Response to Crizotinib

BMC Cancer
Cancer ResearchOncologyGenetics
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy